Form 4: Travere Therapeutics CMO Sells Shares for Tax Obligations

Travere Therapeutics' Chief Medical Officer, Jula Inrig, sold common stock to cover tax withholding obligations related to vested restricted stock units, with one transaction also part of a pre-arranged 10b5-1 plan.

Summary

• Jula Inrig, Chief Medical Officer of Travere Therapeutics, Inc. (TVTX), reported sales of common stock.
• On January 5, 2026, 2,031 shares of common stock were sold at a price of $40.18 per share. This sale was mandated by Travere Therapeutics to cover tax withholding obligations in connection with the settlement of vested restricted stock units and was not a discretionary trade.
• On January 6, 2026, an additional 445 shares of common stock were sold at a price of $37.75 per share. This transaction was executed pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c), and also included shares to cover tax obligations upon the vesting of restricted stock units.
• Following these reported transactions, Jula Inrig beneficially owns 86,311 shares of Travere Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the reported transactions are routine, non-discretionary sales by an officer to cover tax obligations on vested restricted stock units, which is a common and expected event in executive compensation.

Industry Context

This insider transaction report details routine stock sales by a corporate officer, which is a common occurrence in the biotechnology and pharmaceutical industry, often related to compensation structures involving restricted stock units and pre-arranged trading plans.

Stakeholder Impact

• Shareholders: Minimal impact as these are routine, non-discretionary sales for tax purposes, not indicative of a change in management's view of the company's prospects.

Key Dates

Keywords

Travere Therapeutics, TVTX, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, 10b5-1 Plan, Jula Inrig, Chief Medical Officer